GLP1R and early-onset autosomal dominant Alzheimer disease: By modulating neuroinflammatory responses, GLP-1 receptor mimetics hold the promise of reducing the harmful immune activation that contributes to neuronal damage and cognitive decline in Alzheimer’s disease [124,137,142].